Lucid Capital initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $50 price target The firm says Ascentage is a commercial-stage biotechnology company focused on developing next generation tyrosine kinase inhibitors for oncology. The company has the potential to develop and commercialize “differentiated” assets with validated targets in multi-blockbuster opportunities, offering significant upside for somewhat mitigated risk, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025
- Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025
- Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax
- Ascentage Pharma presents data for Lisaftoclax at 2025 ASH
- Ascentage Pharma initiated with an Outperform at Oppenheimer